Genta, Inc (fka GNTAQ)

[Suebarth]

It’s a seller’s market right now, meaning if you’ve got a product to sell that could potentially replace some glaring gaps that have opened up in the big pharma pipeline as the result of a slew of patent expirations, then you’re holding the leverage to hold out and wait for the best deal. Take some recent examples as evidence; GlaxoSmithKline (NYSE:GSK), for instance, made international headlines with an offer to acquire Human Genome Sciences, Inc. (NASDAQ:HGSI). That bid has since gone hostile when Human Genome demanded a better deal. Illumina, Inc. (NASDAQ:ILMN) also rejected two offers from Roche Holding (PINK:RHHBY) – one for $44.50/share and the other for $51/share — and Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) turned away Bristol-Myers Squibb Company (NYSE:BMY) earlier this year on a $3.5 billion, $22/share offer.

Given the boldness with which the potentially-acquired company held out in each case, it’s understandable why smaller companies with potential blockbusters in their belts would also figure to play a significant role in the merger and acquisition arena in due time.

http://marketplayground.com/2012/07/10/buyout-talk-catalysts-and-clinical-results-can-move-these-healthcare-stocks-amrn-gsk-hgsi-ilmn-rhhby-amln-bmy-pbth-teva-lptn-pfe-ssh-mric-si-bsx-ctso/#more-23868